We recently compiled a list of the 10 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) stands against the other AI stocks.
Technology is advancing unprecedentedly, and physical AI seems to be the next leap forward. That’s right, physical AI is going to be an incremental moment for mankind, where intelligent machines will have the ability to interact and manipulate their environment. Manifesting in robots and machines, these advanced systems can analyze their surroundings, use data to make decisions, and even physically interact with the world around them.
READ NOW: Top 10 AI Stocks on Latest Analyst Ratings and News and 15 Important AI News and Ratings on Investors’ Radar
This makes robotics makers, auto suppliers, and specialty semiconductor companies the next big winners in AI. While it initially started with search bots, technology is now moving to agentic AI, such as research assistants and customer service representatives. Naturally, the next focus is going to be technology that can interact with the physical world and act independently through artificial intelligence. According to analysts, this is where all the “big money” is going to be.
“As you go into 2025, agentic AI is that next inflection point here before you hit that physical AI moment … like with everything else in the world, you have to crawl before you can walk and then run. Gen AI hasn’t really seen much monetization thus far. So when you start thinking about agentic AI and robotics and what have you, there’s a real kind of belief out there — and expectation. You’ll see those use cases start to come about this year”.
-CFRA senior equity analyst Angelo Zino.
According to CNBC, Wall Street anticipates realistic AI-enabled agent applications to start appearing this year. Innovations in physical AI could begin coming out later, most likely beginning with self-driving cars.
Physical AI has created “an additional leg to the stool” to the AI build-out phase. “There’s an additional driver now that augments what’s going on today and AI broadly”.
-Goldman Sachs analyst Toshiya Hari.
According to CEO Jensen Huang, “the ChatGPT moment for general robotics is just around the corner”. He said that the company anticipates enabling the development of three key robots in the coming years: agentic agents, self-driving vehicles, and humanoid robots. In this respect, he has also introduced Nvidia’s Cosmos platform for companies looking to train and develop physical AI systems. According to a recent Nvidia press release, the Cosmos platform can generate physics-based videos from several inputs, like video, image text, as well as robot sensor and motion data.
Here is what Oppenheimer analyst Colin Rusch thinks about Physical AI:
“We see physical AI as a nascent interdisciplinary field poised to transform the industrial complex through increased asset productivity and labor efficiency. We see outsized investment return potential in sensing, sensor fusion, compute hardware & software architecture, connectivity, controls, and AI training strategies”.
-Oppenheimer analyst Colin Rusch
All in all, analysts believe AI is going to be a multi-trillion-dollar Total Addressable Market opportunity, particularly on the physical side of things.
For this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A scientist analyzing antibodies in a lab.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)
Number of Hedge Fund Holders: 1
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is a biotechnology company leveraging multi-omics modeling and complex artificial intelligence to discover and develop therapeutic antibodies. On January 17, the company announced the launch of its AI-powered drug development pipeline designed to revolutionize how new treatments are discovered and optimized. IPA is leading the pack in AI-powered drug discovery, with the BioStrand pipeline transforming drug discovery and offering unmatched speed, precision, and transparency. Unlike traditional drug discovery methods that rely on outdated frameworks, IPA’s approach rebuilds processes from scratch. This has led to the creation of LENSai, IPA’s proprietary AI platform. The LENSai™ platform enables AI-driven drug discovery and organizing complex biological data for speeding up discoveries and eliminating inefficiencies. Powered by LENSai’s, the IPA pipeline enables AI-enhanced therapies that in turn ensure the delivery of treatments is groundbreaking, highly effective, and reliable.
“Our AI-powered pipeline represents a major leap forward for IPA. By harnessing AI and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. This pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose”.
-Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies.
Overall IPA ranks 8th on our list of the AI stocks on latest news and ratings. While we acknowledge the potential of IPA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than IPA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and Complete List of All AI Companies Under $2 Billion Market Cap.
Disclosure: None. This article is originally published at Insider Monkey.
